seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

BEVERLY, Mass. and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) — seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the creation of an engineered high-performance transposase enzyme designed to drive superior performance in sequencing applications. The co-development of this new transposase enzyme – called TnX transposase – builds upon a multi-year partnership between the two companies, leveraging Codexis’ strength in enzyme engineering, and seqWell’s expertise in developing tools to improve next-generation sequencing (NGS) performance. Performance data highlighting this enzyme will be presented during the Advances in Genome Biology and Technology (AGBT) General Meeting being held February 5 – 8, 2024 in Orlando, Florida.

Read more at globenewswire.com